Literature DB >> 25769466

Efficacy of the 'intrapulmonary-artery septation' surgical approach for Fontan candidates with unilateral pulmonary arterial hypoplasia†.

Maiko Tachi1, Masaya Murata1, Yujiro Ide1, Hiroki Ito1, Kazuyoshi Kanno1, Kenta Imai1, Kisaburo Sakamoto2.   

Abstract

OBJECTIVES: The bilaterally unbalanced development of pulmonary arteries (PAs), as a result of unilateral pulmonary arterial hypoplasia (PAhypo) makes patients either ineligible for the Fontan operation or candidates for the one-lung Fontan operation. In the present study, we examined the efficacy of intrapulmonary-artery septation (IPAS), a technique we reported in 2007 in which a septation is constructed within the central PA, in patients with unilateral PAhypo.
METHODS: Sixteen patients with unilateral PAhypo and an affected PA index of ≤60 mm(2)/m(2), including non-confluent PA (NCPA), underwent IPAS between January 2000 and March 2012; patients with pulmonary venous obstruction were excluded from this study. We compared the affected PA index values before and after IPAS and after the Fontan operation as well as the bilateral pulmonary blood flow ratio using pulmonary scintigraphy. The post-Fontan operation values of central venous pressure (CVP), pulmonary vascular resistance (PVR), ventricular end-diastolic pressure (VEDP), cardiac index (CI) and arterial oxygen saturation (SaO2) at the most recent cardiac catheterization, as well as the pre-IPAS and post-Fontan New York Heart Association (NYHA) classification levels were examined.
RESULTS: One patient died after IPAS (survival rate, 93.8%). Thirteen (86.7%) of the surviving 15 patients underwent the Fontan operation. The mean PA indexes were 25.5 ± 18.9 mm(2)/m(2) before IPAS and 67.9 ± 34.2 mm(2)/m(2) after IPAS (P = 0.003); the mean PA index was 71.1 ± 50.0 mm(2)/m(2) after the Fontan operation. Restenosis did not occur after the Fontan operation, and the PA diameters were maintained. The mean affected/unaffected lung blood flow ratio was 0.89 ± 0.67. The most recent cardiac catheterization after the Fontan operation indicated the following values: CVP, 11.7 ± 1.8 mmHg; PVR, 1.3 ± 0.4 U m(2); EDP, 5.7 ± 2.0 mmHg; CI, 3.1 ± 0.5 l/min/m(2) and SaO2, 94.9 ± 2.0%. The mean pre-IPAS and post-Fontan NYHA levels were 2.3 ± 0.6 and 1.2 ± 0.4, respectively (P = 0.0002).
CONCLUSIONS: With IPAS, the affected PA diameters increased significantly, and were maintained after the Fontan operation, and continuity of the native PAs was achieved. IPAS is very effective for patients suffering from otherwise intractable diseases.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Fontan; Glenn shunt; One-lung Fontan; Pulmonary artery index; Unilateral pulmonary arterial hypoplasia

Mesh:

Year:  2015        PMID: 25769466     DOI: 10.1093/ejcts/ezv091

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Modification of hemi-Fontan operation for patients with functional single ventricle and anomalous pulmonary venous connection to the superior vena cava: mid-term results.

Authors:  Hiroki Ito; Masaya Murata; Yujiro Ide; Mikio Sugano; Kazuyoshi Kanno; Kenta Imai; Motonori Ishido; Ryohei Fukuba; Kisaburo Sakamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-08

Review 2.  Intrapulmonary artery septation for pulmonary artery growth in functionally univentricular hearts.

Authors:  Maruti Haranal; Balaji Srimurugan; Sivakumar Sivalingam
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-01-23

3.  Management of failing bidirectional cavopulmonary shunt: Influence of additional systemic-to-pulmonary-artery shunt with classic Glenn physiology.

Authors:  Caecilia Euringer; Takashi Kido; Bettina Ruf; Melchior Burri; Paul Philipp Heinisch; Janez Vodiskar; Martina Strbad; Julie Cleuziou; Daniel Dilber; Alfred Hager; Peter Ewert; Jürgen Hörer; Masamichi Ono
Journal:  JTCVS Open       Date:  2022-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.